Abstract:Abstract: OBJECTIVE To explore the therapeutic effect of tenofovir disoproxil fumarate in the treatment of chronic hepatitis B in pregnant women. METHODS 200 pregnant women with chronic hepatitis B admitted to the obstetrics department of Zhangqiu District Maternal and Child Health Hospital in Shandong Province from February 2020 to February 2023 were selected and randomly divided into control group (n＝100) and treatment group (n＝100) by a random number table method. The control group received routine treatment, while the treatment group received tenofovir disoproxil fumarate treatment based on routine treatment. The treatment effects of the two groups were compared. RESULTS After treatment, Hepatitis B virus-dioxyribonuclic acid (HBV-DNA) of the treatment group was (2.51±0.41) IU/mL, and Alanine aminotransferase (ALT) was (27.02±5.00) U/L, which was lower than that of the control group (52.16±7.36) U/L, (5.32±0.31) IU/mL), and the difference was statistically significant (t＝54.669, 28.254, P＜0.05). Hepatitis B surface antigen，Hepatitis B e antigen and contain of HBV-DNA of the neonates in the treatment group at birth and at 12 months of age were lower than that of the control group. CONCLUSION For pregnant women with chronic hepatitis B, the use of tenofovir disoproxil fumarate has outstanding therapeutic effects, which can improve liver function, block mother-to-child transmission, optimize childbirth outcomes, and has high clinical promotion value.